1. Home
  2. ATNM vs UBXG Comparison

ATNM vs UBXG Comparison

Compare ATNM & UBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.10

Market Cap

36.8M

Sector

Health Care

ML Signal

HOLD

Logo U-BX Technology Ltd. Ordinary Shares

UBXG

U-BX Technology Ltd. Ordinary Shares

HOLD

Current Price

$1.06

Market Cap

32.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
UBXG
Founded
2000
2018
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.8M
32.4M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
ATNM
UBXG
Price
$1.10
$1.06
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.50
N/A
AVG Volume (30 Days)
132.5K
30.8K
Earning Date
05-08-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
14.17
N/A
EPS
N/A
N/A
Revenue
$90,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.11
N/A
52 Week Low
$0.95
$1.02
52 Week High
$1.95
$4.49

Technical Indicators

Market Signals
Indicator
ATNM
UBXG
Relative Strength Index (RSI) 49.69 33.96
Support Level $1.02 N/A
Resistance Level $1.25 $2.23
Average True Range (ATR) 0.07 0.35
MACD 0.01 -0.07
Stochastic Oscillator 55.24 1.35

Price Performance

Historical Comparison
ATNM
UBXG

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About UBXG U-BX Technology Ltd. Ordinary Shares

U-BX Technology Ltd focuses on providing value-added services using artificial intelligence-driven technology to businesses in the insurance industry, including insurance carriers and brokers. Its main offerings include three services/products: digital promotion services, risk assessment services, and value-added bundled benefits. The PRC operating entities help their institutional clients gain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or clients' promotion time on these channels. U-BX Beijing developed a unique algorithm named the Magic Mirror. The majority of revenue comes from digital promotion services. Geographically, all of the company's revenue is derived from Mainland China.

Share on Social Networks: